Comment: Defining cure in primary CNS lymphoma

@article{Batchelor2014CommentDC,
  title={Comment: Defining cure in primary CNS lymphoma},
  author={Tracy T. Batchelor},
  journal={Neurology},
  year={2014},
  volume={82},
  pages={1373 - 1373}
}
Primary CNS lymphoma (PCNSL), a type of extranodal non-Hodgkin lymphoma, is a potentially curable brain cancer. Ongoing randomized trials assessing treatments for PCNSL will ultimately establish a standard of care. Until that time, practitioners have multiple treatment options from which to choose. In this report, the authors provide long-term follow-up data from a phase 2 clinical trial in newly diagnosed PCNSL patients, ages 18–70, treated with MATILDE chemotherapy followed by whole-brain… 
View on Publisher
neurology.org

References

SHOWING 1-10 OF 14 REFERENCES
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas
TLDR
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial, finding that myelosuppression was the dose-limiting toxicity.
How I treat primary CNS lymphoma.
TLDR
Level of evidence is low, with consequent uncertainties in therapeutic decisions and lack of consensus on primary endpoints for future trials, resulting in the recent publication of studies on PCNSL's biology and molecular mechanisms and of the first international randomized trials.
MATILDE chemotherapy regimen for primary CNS lymphoma
TLDR
This study provides Class IV evidence that in patients with PCNSL, MATILDE chemotherapy followed by response-tailored radiotherapy increases the probability of disease remission at 12 years, which further proves its long-lasting efficacy with acceptable neurologic deficits.
LONG-TERM OUTCOME IN PCNSL PATIENTS TREATED WITH HIGH-DOSE METHOTREXATE AND DEFERRED RADIATION
TLDR
Follow-up study results from NABTT 96-07, a phase II multicenter trial in which 25 HIV-negative adult patients with newly diagnosed PCNSL were treated with 8 g/m2 of methotrexate IV every 2 weeks until a complete response (CR), as determined by radiographic criteria, was achieved, are reported.
A multicenter study of treatment of primary CNS lymphoma
TLDR
Age, performance status, lactate dehydrogenase serum level, CSF protein level, site of disease, and use of HD-MTX were all predictors of survival, and combined CHT-RT is superior to RT alone.
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
  • A. Ferreri, J. Blay, +20 authors F. Cavalli
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Age, PS, LDH serum level, CSF protein concentration, and involvement of deep structures of the brain were independent predictors of survival and a prognostic score including these five parameters seems advisable in distinguishing different risk groups in PCNSL patients.
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
  • P. Morris, D. Correa, +13 authors A. Omuro
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
R-MPV combined with consolidation rdWBRT and cytarabine is associated with high response rates, long-term disease control, and minimal neurotoxicity in primary CNS lymphoma.
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
  • G. Illerhaus, R. Marks, +7 authors J. Finke
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Sequential systemic methotrexate and AraC and thiotepa followed by HDT plus ASCT and hyperfractionated WBRT is very effective with little toxicity as initial therapy for PCNSL.
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
TLDR
Sequential high-dose MTX containing chemotherapy followed by high- dose carmustine/thiotepa plus ASCT (±whole brain irradiation) is safe and leads to high survival rates in eligible patients with newly diagnosed PCNSL.
Late relapse in primary central nervous system lymphoma: clonal persistence.
TLDR
Patients with late relapses with PCNSL have a good response to salvage therapy and prolonged survival, and the histologic specimens at initial diagnosis and relapse were examined for clonal rearrangement in 3 patients.
...
1
2
...